The erythroid marrow and circulating red blood cells (RBCs) are the key components of the
human erythron. Abnormalities of the erythron that are responsible for anemia can be …

Abstract Sotatercept (ACE-011) is an activin receptor IIA-Fc (ActRIIA-Fc) fusion protein
currently under investigation for its potential in the treatment of hematologic diseases. By …

Congenital dyserythropoietic anemia type II (CDA II) is an inherited autosomal recessive
blood disorder which belongs to the wide group of ineffective erythropoiesis conditions. It is …

The congenital dyserythropoieitic anemias: genetics and path... : Current Opinion in
Hematology The congenital dyserythropoieitic anemias: genetics and pathophysiology : Current …

Congenital dyserythropoietic anemia type II (CDAII) results from loss-of-function mutations in
SEC23B. In contrast to humans, SEC23B-deficient mice deletion do not exhibit CDAII but die …

Biallelic pathogenic variants in the SEC23B gene cause congenital dyserythropoietic
anemia type II (CDA II), a rare hereditary disorder hallmarked by ineffective erythropoiesis …

Congenital hemolytic anemias (CHAs) comprise defects of the erythrocyte membrane
proteins and of red blood cell enzymes metabolism, along with alterations of erythropoiesis …

Sotatercept binds free activins by mimicking the extracellular domain of the activin receptor
type IIA (ACTRIIA). Additional ligands are BMP/TGF‐beta, GDF8, GDF11 and BMP10. The …

Hereditary dyserythropoietic anemias, or congenital dyserythropoietic anemias (CDAs), are
rare disorders disrupting normal erythroid lineage development, resulting in ineffective …

Congenital dyserythropoietic anemia (CDA) is characterized by anemia—mild to severe,
hemolysis, ineffective erythropoiesis, and in some cases, iron overload. There are three …